Nova Mentis Life Science Corp. (NMLSF)
USD 0.03
(0.0%)
USD 0.03
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.2 Million CAD | -3.02% |
| 2022 | -1.84 Million CAD | 62.12% |
| 2021 | -2.79 Million CAD | -115.66% |
| 2020 | -1.79 Million CAD | 1873.23% |
| 2019 | -1.1 Million CAD | 69.62% |
| 2018 | -3.31 Million CAD | -111.01% |
| 2017 | -1.58 Million CAD | 6.3% |
| 2016 | -1.87 Million CAD | -155.5% |
| 2015 | -652.66 Thousand CAD | -166.76% |
| 2014 | -453.37 Thousand CAD | 1062.1% |
| 2013 | -112.56 Thousand CAD | 82.81% |
| 2012 | -654.95 Thousand CAD | 32.96% |
| 2011 | -976.93 Thousand CAD | -40.98% |
| 2010 | -692.98 Thousand CAD | 62.32% |
| 2009 | -1.83 Million CAD | -147.13% |
| 2008 | -744.19 Thousand CAD | -21.17% |
| 2007 | -614.19 Thousand CAD | -503.79% |
| 2006 | -101.72 Thousand CAD | -63.44% |
| 2005 | -62.24 Thousand CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -144.98 Thousand CAD | 34.28% |
| 2024 Q2 | -90.17 Thousand CAD | 37.8% |
| 2023 Q4 | -209.94 Thousand CAD | -10.52% |
| 2023 Q3 | -189.95 Thousand CAD | 37.11% |
| 2023 FY | - CAD | -5.32% |
| 2023 Q1 | -527.27 Thousand CAD | -255.57% |
| 2023 Q2 | -302.06 Thousand CAD | 42.71% |
| 2022 Q2 | -392.83 Thousand CAD | 40.58% |
| 2022 FY | - CAD | 62.12% |
| 2022 Q4 | 338.93 Thousand CAD | 174.98% |
| 2022 Q3 | -452.02 Thousand CAD | -15.07% |
| 2022 Q1 | -661.17 Thousand CAD | -13.87% |
| 2021 Q2 | -422.93 Thousand CAD | 31.45% |
| 2021 Q1 | -616.99 Thousand CAD | -104.37% |
| 2021 Q4 | -580.63 Thousand CAD | 60.24% |
| 2021 FY | - CAD | -115.66% |
| 2021 Q3 | -1.46 Million CAD | -245.3% |
| 2020 Q1 | -118.85 Thousand CAD | -921.74% |
| 2020 Q4 | 14.12 Million CAD | 3106.99% |
| 2020 Q2 | 6.13 Million CAD | 5265.76% |
| 2020 Q3 | -469.73 Thousand CAD | -107.65% |
| 2020 FY | - CAD | 1873.23% |
| 2019 Q3 | -466.87 Thousand CAD | -67.29% |
| 2019 Q4 | -11.63 Thousand CAD | 97.51% |
| 2019 Q2 | -279.07 Thousand CAD | 20.73% |
| 2019 FY | - CAD | 69.62% |
| 2019 Q1 | -352.04 Thousand CAD | 33.75% |
| 2018 Q3 | -702.42 Thousand CAD | -145.24% |
| 2018 FY | - CAD | -111.01% |
| 2018 Q4 | -531.42 Thousand CAD | 24.34% |
| 2018 Q1 | -2.11 Million CAD | -166.19% |
| 2018 Q2 | -286.41 Thousand CAD | 86.45% |
| 2017 FY | - CAD | 6.3% |
| 2017 Q4 | -793.84 Thousand CAD | -136.26% |
| 2017 Q3 | -336 Thousand CAD | -0.39% |
| 2017 Q2 | -334.7 Thousand CAD | -25.78% |
| 2017 Q1 | -266.1 Thousand CAD | 83.21% |
| 2016 Q4 | -1.58 Million CAD | -717.56% |
| 2016 Q3 | -193.9 Thousand CAD | -1242.43% |
| 2016 Q2 | 16.97 Thousand CAD | 119.96% |
| 2016 Q1 | -85.04 Thousand CAD | 64.97% |
| 2016 FY | - CAD | -155.5% |
| 2015 Q2 | -120.04 Thousand CAD | 29.53% |
| 2015 FY | - CAD | -166.76% |
| 2015 Q4 | -242.79 Thousand CAD | -27.91% |
| 2015 Q1 | -170.35 Thousand CAD | -111.83% |
| 2015 Q3 | -189.8 Thousand CAD | -58.11% |
| 2014 Q1 | -72.33 Thousand CAD | -168.99% |
| 2014 Q2 | -141.51 Thousand CAD | -95.65% |
| 2014 FY | - CAD | 1062.1% |
| 2014 Q4 | 1.44 Million CAD | 1101.76% |
| 2014 Q3 | -143.81 Thousand CAD | -1.62% |
| 2013 Q4 | 104.83 Thousand CAD | 215.36% |
| 2013 Q3 | -90.87 Thousand CAD | -33.75% |
| 2013 Q2 | -67.94 Thousand CAD | -19.18% |
| 2013 Q1 | -57.01 Thousand CAD | 61.33% |
| 2013 FY | - CAD | 82.81% |
| 2012 FY | - CAD | 32.96% |
| 2012 Q4 | -147.42 Thousand CAD | 30.22% |
| 2012 Q3 | -211.27 Thousand CAD | -64.05% |
| 2012 Q2 | -128.78 Thousand CAD | 18.61% |
| 2012 Q1 | -158.23 Thousand CAD | 50.63% |
| 2011 Q2 | -282.71 Thousand CAD | -61.59% |
| 2011 FY | - CAD | -40.98% |
| 2011 Q3 | -198.75 Thousand CAD | 29.7% |
| 2011 Q1 | -174.95 Thousand CAD | 87.47% |
| 2011 Q4 | -320.51 Thousand CAD | -61.26% |
| 2010 FY | - CAD | 62.32% |
| 2010 Q3 | 15.81 Thousand CAD | 109.56% |
| 2010 Q2 | -165.43 Thousand CAD | -119.4% |
| 2010 Q4 | -1.39 Million CAD | -8928.0% |
| 2010 Q1 | 852.96 Thousand CAD | 314.46% |
| 2009 Q4 | -397.72 Thousand CAD | 13.43% |
| 2009 Q1 | -605.93 Thousand CAD | -231.02% |
| 2009 FY | - CAD | -147.13% |
| 2009 Q2 | -375.99 Thousand CAD | 37.95% |
| 2009 Q3 | -459.44 Thousand CAD | -22.19% |
| 2008 Q3 | -322.67 Thousand CAD | -71.55% |
| 2008 FY | - CAD | -21.17% |
| 2008 Q1 | -51.5 Thousand CAD | 83.48% |
| 2008 Q4 | -183.05 Thousand CAD | 43.27% |
| 2008 Q2 | -188.09 Thousand CAD | -265.2% |
| 2007 Q2 | -94.71 Thousand CAD | 1.89% |
| 2007 Q3 | -101.95 Thousand CAD | -7.64% |
| 2007 Q4 | -311.79 Thousand CAD | -205.82% |
| 2007 FY | - CAD | -503.79% |
| 2007 Q1 | -96.54 Thousand CAD | -78.92% |
| 2006 FY | - CAD | -63.44% |
| 2006 Q4 | -53.95 Thousand CAD | -216.39% |
| 2006 Q3 | -17.05 Thousand CAD | -13.23% |
| 2006 Q2 | -15.06 Thousand CAD | -10276.35% |
| 2006 Q1 | 148.00 CAD | 0.0% |
| 2005 FY | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 98.307% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 79.721% |
| SQZ Biotechnologies Company | -64.14 Million USD | 98.126% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 93.078% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 101.279% |
| Mesoblast Limited | -62.38 Million USD | 98.073% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 21.728% |
| Genus plc | 73.7 Million USD | 101.631% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 81.815% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 66.104% |
| Marizyme, Inc. | -34.28 Million USD | 96.493% |
| ContraFect Corporation | -64.99 Million USD | 98.15% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 86.294% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 73.437% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 14.232% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 54.535% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 48.262% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -132.083% |
| Accustem Sciences Inc. | -3.74 Million USD | 67.908% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 97.507% |
| EV Biologics, Inc. | -1.26 Million USD | 5.117% |
| Q BioMed Inc. | -617.62 Thousand USD | -94.664% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 133.659% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -90.115% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 47.371% |
| Biomind Labs Inc. | -1.03 Million USD | -16.215% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 112.173% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 83.211% |
| Skye Bioscience, Inc. | -13.54 Million USD | 91.125% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 19.168% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -4709.196% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 69.047% |
| IMV Inc. | -35.52 Million USD | 96.615% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 92.424% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 51.946% |
| GB Sciences, Inc. | -1.41 Million USD | 15.324% |
| Alpha Cognition Inc. | -9.7 Million USD | 87.612% |
| HST Global, Inc. | -5303.00 USD | -22572.054% |
| CSL Limited | 4.78 Billion USD | 100.025% |
| Halberd Corporation | -74.27 Thousand USD | -1518.626% |
| Enzolytics Inc. | -2.12 Million USD | 43.342% |
| Resverlogix Corp. | -11.74 Million USD | 89.761% |
| Affymax, Inc. | -14.29 Million USD | 91.589% |
| SYBLEU INC | -141.57 Thousand USD | -749.255% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 60.748% |
| argenx SE | -216.02 Million USD | 99.443% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 97.827% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 198.792% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 19.788% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 417.36% |
| AVAX Technologies, Inc. | -6.11 Million USD | 80.331% |
| Zenith Capital Corp. | -8.6 Million USD | 86.03% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.517% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -6801.435% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 50.856% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -583.03% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 96.967% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 58.431% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -14.908% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 17980.711% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 31.297% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 37.41% |
| BioStem Technologies, Inc. | -7.55 Million USD | 84.083% |
| ONE Bio Corp. | 13.61 Million USD | 108.832% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -563.931% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 41.551% |
| Agentix Corp. | -1.37 Million USD | 12.353% |
| LadRx Corporation | 412.28 Thousand USD | 391.62% |
| Cell Source, Inc. | -4.27 Million USD | 71.86% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -227.405% |
| Regen BioPharma, Inc. | 1.46 Million USD | 182.015% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -28.321% |
| NovAccess Global Inc. | -1.03 Million USD | -16.187% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 113.579% |
| Itoco Inc. | -1.86 Million USD | 35.671% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -216.711% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -7.733% |
| Kadimastem Ltd | -2.62 Million USD | 54.187% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -402.738% |
| CytoDyn Inc. | -18.02 Million USD | 93.331% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -1421.339% |
| Mobile Lads Corp. | -2.24 Million USD | 46.354% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -9731.54% |
| Qrons Inc. | -40.08 Thousand USD | -2899.673% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -147.551% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 327.953% |
| Rebus Holdings, Inc. | -951 Thousand USD | -26.425% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -13.21% |
| International Stem Cell Corporation | 202 Thousand USD | 695.198% |
| Bioxytran, Inc. | -3.82 Million USD | 68.527% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -2184.003% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 51.164% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 96.648% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -2571.776% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 56.088% |
| Neutra Corp. | -181.24 Thousand USD | -563.348% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 94.036% |
| PureTech Health plc | -11.62 Million USD | 89.659% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 94.036% |
| IXICO plc | -707 Thousand USD | -70.056% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 84.355% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 97.513% |
| CSL Limited | 4.73 Billion USD | 100.025% |
| Cellectis S.A. | -92.63 Million USD | 98.702% |